Essential Thrombocythemia
SURPASS-ET
ENROLLING: A Phase 3 open-label, multicenter, randomized, active-controlled study designed to compare the efficacy and safety and tolerability of ropeginterferon alfa-2b-njft compared with an available treatment as second-line therapy for adults with essential thrombocythemia (ET). For more information, please visit www.SurpassET.com or www.clinicaltrials.gov (NCT04285086).
EXCEED-ET
ENROLLING: A Single-arm, multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft for adults with essential thrombocythemia (ET). More information on the study, including eligibility criteria, can be found by visiting www.ExceedET.com or www.clinicaltrials.gov (NCT05482971).